Genomtec

Genomtec CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Genomtec (GMT.WA) as of Oct 15, 2026 is -0.81 %. In the previous year, CapEx to Operating Cash Flow Ratio was -0.88 % — a change of -8.01% (higher).

CapEx/OCF

-0.81 %

YoY

-8.01%

Last updated:

CapEx to Operating Cash Flow Ratio of Genomtec is 2025 -0.81 % . CapEx to Operating Cash Flow Ratio of Genomtec was 2024 -0.88 % . It decreases by -8.01% higher compared to the previous year.

The Genomtec CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
-28.96 PLN
Jan 1, 2020
-5.05 PLN
Jan 1, 2021
-3.85 PLN
Jan 1, 2022
-114.42 PLN
Jan 1, 2023
-44.35 PLN
Jan 1, 2024
-0.88 PLN
Jan 1, 2025
-0.81 PLN
The Genomtec CapEx/OCF history
YEARCapEx/OCFYoY
-0.81 %-8.01%
-0.88 %-98.02%
-44.35 %-61.24%
-114.42 %+2,869.49%
-3.85 %-23.70%
-5.05 %-82.56%
-28.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomtec Stock analysis

What does Genomtec do? Genomtec SA is a company based in Wrocław, Poland, listed on the Warsaw Stock Exchange under the ticker GMT.WA. It has an ISIN code of PLGNMTC00017 and went public through an IPO on March 17, 2021. The company operates in the field of molecular diagnostics, focusing on the research and development of diagnostic equipment. Genomtec SA is known for developing the Genomtec ID platform, a mobile solution designed for genetic diagnosis at the point of patient care. This platform enables diagnostic procedures to be conducted in settings such as primary care clinics, pharmacies, doctor’s offices, and hospital emergency departments without requiring complex laboratory workflows or specialized personnel. The company's technology aims to streamline the diagnostic process, making it more accessible and efficient in various healthcare environments. Genomtec SA's headquarters are located in Wrocław, within the Lower Silesian Voivodeship. The company's website is https://genomtec.com/, where further information about its products and services can be found. As of the available information, Genomtec SA is active in the development and commercialization of its mobile diagnostic platform, targeting healthcare providers seeking to integrate rapid genetic testing into their practice. The company does not specify its sector or industry in the provided data, but it is clearly engaged in medical technology innovation. Genomtec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomtec stock

CapEx to Operating Cash Flow Ratio of Genomtec is -0.81 % in 2025.

CapEx to Operating Cash Flow Ratio of Genomtec changed from -0.88 % to -0.81 %, representing a -8.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Genomtec since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Genomtec with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genomtec

All Key Metrics — Genomtec